Jun 30, 2022 9:00am EDT Avalon GloboCare Announces New Study Featuring AI-Enhanced Protein Design Technology Targeting Glucose Transporter Against Cancer
May 18, 2022 9:00am EDT Avalon GloboCare Signs MOU to Form Strategic Partnership with Lu Daopei Hematology Institute to Develop Precision Companion Diagnostics for Cellular Therapy
Feb 14, 2022 9:00am EST Avalon GloboCare Expands its Cellular Immuno-Oncology Platform with the Addition of Novel Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapies
Jan 04, 2022 9:00am EST Avalon GloboCare Provides Year-End Business Update of Selective Scientific and Clinical Programs
Dec 22, 2021 9:00am EST Avalon GloboCare’s Chairman Converts Debt into Common Stock at 45% Premium to Market
Oct 14, 2021 9:20am EDT Avalon GloboCare Jointly Files US and International Patent Application for Breakthrough S-Layer Coated Emulsome Technology (SLET) for Next-Generation Drug Delivery and Cellular Immunotherapy
Oct 07, 2021 9:00am EDT Avalon GloboCare and University of Natural Resources and Life Sciences (BOKU) Co-develop Innovative In-Silico Technology, Enabling the Design and Synthesis of Novel Cell Membrane Receptor Targets for Cancer and Immune-Related Diseases
Sep 23, 2021 9:00am EDT Avalon GloboCare to Present at the Benzinga Healthcare Small Cap Conference on September 30th